Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $0, compared with $0 a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Other non-current liabilities amounts to 0.0% of total assets for UNCY, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $56.19M USD | +2809550.0% | — | 53.3% | |
| Mar 2026 | $18.37M USD | — | — | 39.6% | |
| Mar 2026 | $3.74M USD | +49714.6% | — | 1.6% | |
| Mar 2026 | $3.21M USD | +270.6% | +147.4% | 1.8% | |
CBUSCibus, Inc. | Mar 2026 | $1.58M USD | -99.2% | +170.3% | 0.5% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $0 USD | — | — | 0.0% |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$0 CAD | +100.0% | — | 0.0% |
| Peer median (excluding UNCY) | — | +270.6% | +158.9% | 0.5% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.